Archemix Merger with NitroMed Falls Through

Archemix Corp., a Cambridge, Mass.-based developer of aptamer-based therapeutics, has lost its bid to go public via a reverse merger with NitroMed Inc. (Nasdaq: NTMD), after NitroMed accepted a richer offer from Deerfield Management. Archemix received a $1.5 milion termination fee.

Archemix has raised around $135 million in VC funding from firms like Atlas Venture (13.9% stake), Prospect Venture Partners (13.9%), Highland Capital Parnters (13.2%), SV Life Sciences (11.6%), KGaA (11.3%), Rho Ventures (9.6%) and Care Capital (5.3%).

Leave a Reply

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget